Skip to main content
Premium Trial:

Request an Annual Quote

Jay Lichter, Dereck Tatman, Murlai Prahalad, Pete De Spain, James Greenwood, Carl Feldbaum, Emanuel Petricoin, Lance Liotta, Ronald Andrews, Michael Cola, Eric Fung

Premium

Jay Lichter, executive vice president of business development at Sequenom, has left the company, an outside company spokesperson confirmed last week. Dereck Tatman and Murlai Prahalad, who serve as directors of business development at Sequenom, have assumed his duties. In addition, Pete De Spain, manager of corporate communications at the San Diego company, has left to become manager of corporate communications at Anadys Pharmaceuticals, also of San Diego.


Congressman James Greenwood, who recently held hearings on Capitol Hill to see whether two proteomics researchers at the National Cancer Institute violated conflict of interest rules, will leave the US House of Representatives to become president of the Biotechnology Industry Organization. He replaces Carl Feldbaum.

Greenwood, who represents Bucks County, Pa., cancelled congressional hearings on the link between antidepressants and suicide this week to avoid the appearance of a conflict of interest. As BIO president, Greenwood will be paid an annual base salary of $650,000, plus bonus incentives worth $200,000, according to news reports. He earned $158,100 as a US representative.

Greenwood, a Republican, is chairman of the US Congressional Subcommittee on Oversight and Investigations, which has been investigating consulting and awards ethics at the NIH during a series of hearings earlier this month. He has called NCI and US Food and Drug Administration approval of consulting activities by Emanuel Petricoin and Lance Liotta of the NCI-FDA Clinical Proteomics program an “outrage.” Read the article by ProteoMonitor, Pharmacogenomics Reporter’s sister publication, for details.


ChromaVision Medical Systems has hired Roche Molecular Diagnostics veteran Ronald Andrews as president and CEO, the company said last week. Andrews will replace Michael Cola, the chairman of the board, who has served as interim CEO since February 2004.

At Roche, Andrews was senior vice president of marketing and commercial business development.


Eric Fung has been promoted by Ciphergen to the position of vice president of clinical and medical affairs, in its new diagnostics division, the company said July 14. Fung will manage clinical and medical research underlying the company’s clinical diagnostics business initiative in the area of protein molecular diagnostics.

Fung was most recently director of clinical affairs at Ciphergen, which he joined in 2000 as a lead scientist in its Biomarker Discovery Center laboratories.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.